Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer-Reference-Cited by-同舟云学术

Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer

Published:2024-09-13 Issue:1 Volume:23 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Chen Yonger,Liang Jian,Chen Shuxian,Lin Nan,Xu Shuoxi,Miao Jindian,Zhang Jing,Chen Chen,Yuan Xin,Xie Zhuoya,Zhu Enlin,Cai Mingsheng,Wei Xiaoli,Hou Shaozhen,Tang Hailin

Funder

Natural Science Foundation of Guangdong Province

National Natural Science Foundation of China

Foundation and Applied Basic Research Fund Project of Guangdong Province

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12943-024-02108-6.pdf

Reference51 articles.

1. Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O’Brien SA, He Y, Wang L, Zhang Q, Kim A, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in Colon cancer. Cell. 2020;181:442–+.

2. Fujita M, Matsubara N, Matsuda I, Maejima K, Oosawa A, Yamano T, Fujimoto A, Furuta M, Nakano K, Oku-Sasaki A, et al. Genomic landscape of colitis-associated cancer indicates the impact of chronic inflammation and its stratification by mutations in the wnt signaling. Oncotarget. 2018;9:969–81.

3. Wang X, Chen JDZ. Therapeutic potential and mechanisms of sacral nerve stimulation for gastrointestinal diseases. J Translational Intern Med. 2023;11:115–27.

4. Xu Y, Liu K, Li C, Li M, Liu F, Zhou X, Sun M, Ranganathan M, Zhang L, Wang S et al. The largest Chinese cohort study indicates homologous recombination pathway gene mutations as another major genetic risk factor for colorectal Cancer with heterogeneous clinical phenotypes. Research 2023, 6.

5. Yaeger R, Shah MA, Miller VA, Kelsen JR, Wang K, Heins ZJ, Ross JS, He Y, Sanford E, Yantiss RK, et al. Genomic alterations observed in Colitis-Associated Cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology. 2016;151:278–.